NCT02166242View on ClinicalTrials.gov

Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2014

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2021

Conditions
Carcinoma, Non-small Cell Lung
Interventions
DRUG

ethaselen

ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated

Trial Locations (1)

Unknown

Hunan province tumor hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER

NCT02166242 - Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers | Biotech Hunter | Biotech Hunter